European Journal of Cancer
Volume 45, Issue 1 , Pages 82-89 , January 2009

Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study

  • Trond M. Michelsen

      Affiliations

    • Department of Gynaecology, Sørlandet Hospital Arendal, Service Box 605, N-4809 Arendal, Norway
    • National Resource Centre for Women’s Health, Rikshospitalet University Hospital, 0027 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Address: Department of Gynaecology, Sørlandet Hospital Arendal, Service Box 605, N-4809 Arendal, Norway. Tel.: +47 37014000; fax: +47 37014041.
    • ,
  • Are H. Pripp

      Affiliations

    • Biostatistics Unit, Rikshospitalet University Hospital, 0027 Oslo, Norway
    • ,
  • Serena Tonstad

      Affiliations

    • Department of Internal Medicine, Ullevål University Hospital, University of Oslo Division, 0407 Oslo, Norway
    • ,
  • Claes G. Tropé

      Affiliations

    • Department of Gynaecologic Oncology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, University of Oslo Division, 0310 Oslo, Norway
    • ,
  • Anne Dørum

      Affiliations

    • Department of Gynaecologic Oncology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, University of Oslo Division, 0310 Oslo, Norway

Received 19 July 2008 ,Revised 12 September 2008 ,Accepted 30 September 2008.

References 

  1. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. New Engl J Med. 1998;339:424–428
  2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–1333
  3. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296:185–192
  4. Narod SA. Modifiers of risk of hereditary breast cancer. Oncogene. 2006;25:5832–5836
  5. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331–1337
  6. Jacobs AK. Women, ischemic heart disease, revascularization, and the gender gap: what are we missing?. J Am Coll Cardiol. 2006;47:S63–S65
  7. Polk DM, Naqvi TZ. Cardiovascular disease in women: sex differences in presentation, risk factors, and evaluation. Curr Cardiol Rep. 2005;7:166–172
  8. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006;13:265–279
  9. Rocca WA, Grossardt BR, de A, Malkasian GD, Melton LJ. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7:821–828
  10. Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas. 2006;53:226–233
  11. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007;14:373–384
  12. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428
  13. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet. 2005;366:1059–1062
  14. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486–97.
  15. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066–1076
  16. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey 1988–1994. Arch Intern Med. 2003;163:427–436
  17. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404–2411
  18. Dorum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol. 2008;
  19. Holmen J, Midthjell K, Kruger Ø, et al. The Nord-Trøndelag Health Study 1995–1997 (HUNT 2): objectives, contents, methods and participation. Norwegian J Epidemiol. 2003;13:19–32
  20. Thorsen L, Nystad W, Stigum H, et al. The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer. 2005;13:637–646
  21. Beaulieu LM, Whitley BR, Wiesner TF, et al. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays. 2007;29:1029–1038
  22. Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004;96:1152–1160
  23. Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer. 2006;13:279–292
  24. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007;8:395–408
  25. Schwartz CE, Sprangers MAG. Adaptation to changing health: response shift in quality of life research; 2000.
  26. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–880
  27. Nkondjock A, Robidoux A, Paredes Y, Narod SA, Ghadirian P. Diet, lifestyle and BRCA-related breast cancer risk among French–Canadians. Breast Cancer Res Treat. 2006;98:285–294
  28. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA. 1996;275:1885–1892
  29. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79:379–384
  30. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23:7804–7810

PII: S0959-8049(08)00786-7

doi: 10.1016/j.ejca.2008.09.028

European Journal of Cancer
Volume 45, Issue 1 , Pages 82-89 , January 2009

Article Tools